Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
| ▸ | CFB | P00751 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19539601 | 0.95 | CHRNB2 (0.61) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL674978 | 0.83 | CHRNB2 (0.54) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL11444309 | 0.83 | CHRNB2 (0.54) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7738292 | 0.83 | CHRNB2 (0.54) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL24310101 | 0.81 | CHRNB2 (0.59) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7738331 | 0.81 | CHRNB2 (0.51) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL16130801 | 0.80 | CYP19A1 (0.47) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3663312 | 0.80 | CFB (0.46) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL19865697 | 0.79 | CHRNB2 (0.62) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13452380 | 0.79 | CHRNB2 (0.61) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150197524-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-07-16 | — | — | US | disclosed |
| US-8846693-B2 | Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20100273753-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273753-A1 | ORGANIC COMPOUNDS | OPRD1, PGR, HTR1D | CHRNB2 66/4885CHRNA7 64/4885CHRNA4 75/4885 |
| US-20150197524-A1 | ORGANIC COMPOUNDS | OPRD1, HTR1D, DRD1 | CHRNB2 64/4885CHRNA7 51/4885CHRNA4 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.